Stereotactic body radiation therapy for liver metastasis from colorectal cancer: size matters

• Published in: Clinical & translational oncology Vol. 22; no. 12; pp. 2350 - 2356
• Main Authors: Flamarique, S., Campo, M., Asín, G., Pellejero, S., Viúdez, A., Arias, F.
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.12.2020
• Subjects: Brief Research Article; Medicine; Medicine & Public Health; Oncology; Hepatic metastasis; Colorectal cancer; SBRT
• ISSN: 1699-048X; 1699-3055
• DOI: 10.1007/s12094-020-02375-x

Purpose We analysed our initial experience with SBRT in liver metastasis from colorectal cancer at our institution. Materials and methods Between January/2014 and December/2017, 22 patients with 31 LMCCR were treated. Local control (LC) was assessed using the Kaplan–Meier and log-rank tests. We analysed potential prognostic factors for LC: sex, PTV size, number of LM and the radiation scheme. Results Median age: 69 years. Prior chemotherapy or local liver treatments: 81.8% and 63.6% of patients, respectively. SBRT consisted of 3 × 20 Gy (42.9%) and 3 × 15 Gy (31.4%). There were 88.5% responses (57.1% CR and 31.4% PR). Median follow-up was 30 months. LC per lesion at 12 and 24 months was 85.3% and 61.8%, respectively. Tumour volumes > 30 cc correlated with worsened 2-year-control rates (90% vs 34.5%) ( p  = 0.005). There was only a patient with CTC-grade 3 toxicity. Conclusions Liver SBRT is a safe and effective treatment that achieves high local control rates. We found a significant correlation between larger LMCRC and worse local control.